Search Results

Site Search

Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC - Insights

Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many...

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC - Insights

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related...

New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. - Insights

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test...

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S. - Insights

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating...

Tests Aid Diagnosis of Cancer-Associated Neurological Disorders: Divyanshu Dubey, M.B.B.S. - Insights

Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing...

Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D. - Insights

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of...

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D. - Insights

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's...

Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D. - Insights

Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost...

Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection: Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S. - Insights

Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted...

Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.